Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Cross Above 200-Day Moving Average of $10.85

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $10.85 and traded as high as $11.29. Global X Genomics & Biotechnology ETF shares last traded at $11.25, with a volume of 25,806 shares trading hands.

Global X Genomics & Biotechnology ETF Stock Performance

The company has a 50 day moving average of $11.25 and a 200 day moving average of $10.85. The stock has a market capitalization of $83.70 million, a price-to-earnings ratio of -4.81 and a beta of 1.03.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Centaurus Financial Inc. acquired a new position in Global X Genomics & Biotechnology ETF in the 2nd quarter valued at $146,000. Sanctuary Advisors LLC acquired a new position in Global X Genomics & Biotechnology ETF in the 2nd quarter valued at $590,000. One Capital Management LLC raised its stake in Global X Genomics & Biotechnology ETF by 22.1% in the 2nd quarter. One Capital Management LLC now owns 680,311 shares of the company’s stock valued at $7,102,000 after purchasing an additional 123,339 shares during the last quarter. Oppenheimer Asset Management Inc. raised its stake in Global X Genomics & Biotechnology ETF by 10.2% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 67,712 shares of the company’s stock valued at $707,000 after purchasing an additional 6,260 shares during the last quarter. Finally, Archford Capital Strategies LLC raised its stake in Global X Genomics & Biotechnology ETF by 59.1% in the 2nd quarter. Archford Capital Strategies LLC now owns 36,871 shares of the company’s stock valued at $385,000 after purchasing an additional 13,703 shares during the last quarter. 56.95% of the stock is owned by institutional investors and hedge funds.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.